<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04448821</url>
  </required_header>
  <id_info>
    <org_study_id>NM-DDI</org_study_id>
    <nct_id>NCT04448821</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Effect of Nilotinib on the PK/PD of Meformin</brief_title>
  <official_title>A Clinical Trial to Evaluate the Effect of Nilotinib on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Male Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hyewon Chung</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea University Guro Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the effect of nilotinib on the pharmacokinetics and
      pharmacodynamics of metformin in healthy male adults
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pharmacokinetics and pharmacodynamics of metformin without coadministration of nilotinib will
      be compared with those after administration of nilotinib.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 6, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>24 hours post-dose</time_frame>
    <description>maximum concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf</measure>
    <time_frame>24 hours post-dose</time_frame>
    <description>Area under the concentration-time curve from time of administration extrapolated to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gmax</measure>
    <time_frame>3 hours from 2 hour post-dose</time_frame>
    <description>maximum glucose level during oral glucose tolerance test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUGC</measure>
    <time_frame>3 hours from 2 hour post-dose</time_frame>
    <description>Area under the concentration-time curve during oral glucose tolerance test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Taste test</measure>
    <time_frame>7 hour post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: metformin; Period 2: metformin + nilotinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: metformin + nilotinib; Period 2: metformin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Single administration of metformin</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin + Nilotinib</intervention_name>
    <description>Coadministration of metformin and nilotinib</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects between the ages of 19 and 50 years

          -  Subjects with body mass index (BMI) between 18.5 and 29.9 kg/m2 and weight more than
             50 kg

          -  Subjects who agree with performing contraception during the study

          -  Subjects who provides written informed consent

        Exclusion Criteria:

          -  Subjects who have a current or prior history of cardiovascular, respiratory, hepatic,
             renal, hematological, gastrointestinal, endocrine, immunologic, skin, psychiatric, or
             neurological diseases that is clinically significant

          -  Subjects who have clinically significant allergic history or allergy to metformin,
             nilotinib, or other components of drug

          -  Subjects with history of galactose intolerance, lapp lactase deficiency, or
             glucose-galactose malabsorption

          -  Subjects with hypokalemia or hypomagnesemia at screening

          -  Subjects with QTcF &gt; 450 or clinically significant findings on 12-lead ECG at
             screening

          -  Subjects with fasting plasma glucose lower than 70 mg/dL or upper than 126 mg/dL at
             screening

          -  Subjects who have history of gastrointestinal surgery

          -  Subjects with creatinine clearance ≤ 60mL/min at screening

          -  Subjects with AST or ALT ≥ 2-folds of upper normal limit

          -  Subjects who reports less than 12 points on taste test at screening

          -  Subjects who have administrated drugs that are known to cause significant drug-drug
             interaction with investigational drugs within 2 weeks prior to dosing

          -  Whole blood donation within 60 days prior to dosing, or apheresis donation within 20
             days prior to dosing, or received blood donation within 30 days prior to dosing

          -  Subjects who participated in a previous clinical trial within 6 months prior to dosing

          -  Subjects with a history of alcohol abuse

          -  Subjects who are determined as unsuitable for clinical trial participation by
             investigator's decision
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyewon Chung, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Assistant Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyewon Chung, MD, PhD</last_name>
    <phone>02-2626-2550</phone>
    <email>hyewonchung@kumc.or.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Guro-gu</state>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung-hoe Song, MBE</last_name>
      <phone>82-2-2626-1635</phone>
      <email>ssessong@korea.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Ji-young Lee</last_name>
      <phone>82-2-2626-2279</phone>
      <email>ljy@kumc.or.kr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick CM, Ray JE, Timmins P, Williams KM. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011 Feb;50(2):81-98. doi: 10.2165/11534750-000000000-00000. Review.</citation>
    <PMID>21241070</PMID>
  </reference>
  <reference>
    <citation>Chen EC, Liang X, Yee SW, Geier EG, Stocker SL, Chen L, Giacomini KM. Targeted disruption of organic cation transporter 3 attenuates the pharmacologic response to metformin. Mol Pharmacol. 2015 Jul;88(1):75-83. doi: 10.1124/mol.114.096776. Epub 2015 Apr 28.</citation>
    <PMID>25920679</PMID>
  </reference>
  <reference>
    <citation>Kwon EY, Chung JY, Park HJ, Kim BM, Kim M, Choi JH. OCT3 promoter haplotype is associated with metformin pharmacokinetics in Koreans. Sci Rep. 2018 Nov 16;8(1):16965. doi: 10.1038/s41598-018-35322-6.</citation>
    <PMID>30446679</PMID>
  </reference>
  <reference>
    <citation>Lapczuk-Romanska J, Busch D, Gieruszczak E, Drozdzik A, Piotrowska K, Kowalczyk R, Oswald S, Drozdzik M. Membrane Transporters in Human Parotid Gland-Targeted Proteomics Approach. Int J Mol Sci. 2019 Sep 28;20(19). pii: E4825. doi: 10.3390/ijms20194825.</citation>
    <PMID>31569384</PMID>
  </reference>
  <reference>
    <citation>Lee N, Duan H, Hebert MF, Liang CJ, Rice KM, Wang J. Taste of a pill: organic cation transporter-3 (OCT3) mediates metformin accumulation and secretion in salivary glands. J Biol Chem. 2014 Sep 26;289(39):27055-64. doi: 10.1074/jbc.M114.570564. Epub 2014 Aug 8.</citation>
    <PMID>25107910</PMID>
  </reference>
  <reference>
    <citation>Minematsu T, Giacomini KM. Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Mol Cancer Ther. 2011 Mar;10(3):531-9. doi: 10.1158/1535-7163.MCT-10-0731. Epub 2011 Jan 20.</citation>
    <PMID>21252289</PMID>
  </reference>
  <reference>
    <citation>Rhee SJ, Choi Y, Lee S, Oh J, Kim SJ, Yoon SH, Cho JY, Yu KS. Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects. Drug Des Devel Ther. 2016 Aug 10;10:2525-34. doi: 10.2147/DDDT.S110712. eCollection 2016.</citation>
    <PMID>27570447</PMID>
  </reference>
  <reference>
    <citation>Jang K, Chung H, Yoon JS, Moon SJ, Yoon SH, Yu KS, Kim K, Chung JY. Pharmacokinetics, Safety, and Tolerability of Metformin in Healthy Elderly Subjects. J Clin Pharmacol. 2016 Sep;56(9):1104-10. doi: 10.1002/jcph.699. Epub 2016 Feb 22.</citation>
    <PMID>26710683</PMID>
  </reference>
  <reference>
    <citation>Hwang CS, Kim JW, Al Sharhan SS, Kim JW, Cho HJ, Yoon JH, Kim CH. Development of a Gustatory Function Test for Clinical Application in Korean Subjects. Yonsei Med J. 2018 Mar;59(2):325-330. doi: 10.3349/ymj.2018.59.2.325.</citation>
    <PMID>29436203</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 24, 2020</study_first_submitted>
  <study_first_submitted_qc>June 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2020</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Korea University Guro Hospital</investigator_affiliation>
    <investigator_full_name>Hyewon Chung</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

